Literature DB >> 3257544

A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

K C Deen1, J S McDougal, R Inacker, G Folena-Wasserman, J Arthos, J Rosenberg, P J Maddon, R Axel, R W Sweet.   

Abstract

CD4 (T4) is a glycoprotein of relative molecular mass 55,000 (Mr 55K) on the surface of T lymphocytes which is thought to interact with class II MHC (major histocompatibility complex) molecules, mediating efficient association of helper T cells with antigen-bearing targets. The CD4 protein is also the receptor for HIV, a T-lymphotropic RNA virus responsible for the human acquired immune deficiency syndrome (AIDS) (refs 4-7). To define the mechanisms of interaction of CD4 with the surface of antigen-presenting cells and with HIV, we have isolated the CD4 gene and expressed this gene in several different cellular environments. Here we describe an efficient expression system in which a recombinant, soluble form of CD4 (sCD4) is secreted into tissue culture supernatants. This sCD4 retains the structural and biological properties of CD4 on the cell surface, binds to the envelope glycoprotein (gp110) of HIV and inhibits the binding of virus to CD4+ lymphocytes, resulting in a striking inhibition of virus infectivity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257544     DOI: 10.1038/331082a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  180 in total

1.  Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.

Authors:  D Schenten; L Marcon; G B Karlsson; C Parolin; T Kodama; N Gerard; J Sodroski
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Soluble receptor-induced retroviral infection of receptor-deficient cells.

Authors:  R Damico; P Bates
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step.

Authors:  Georgia D. Tomaras; Michael L. Greenberg
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

4.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1.

Authors:  Che Ma; Francesca M Marassi; David H Jones; Suzana K Straus; Stephan Bour; Klaus Strebel; Ulrich Schubert; Myrta Oblatt-Montal; Mauricio Montal; Stanley J Opella
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

6.  Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex.

Authors:  T R Fouts; R Tuskan; K Godfrey; M Reitz; D Hone; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.

Authors:  R A Byrn; I Sekigawa; S M Chamow; J S Johnson; T J Gregory; D J Capon; J E Groopman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Analytic results for quantifying HIV infectivity.

Authors:  J L Spouge; S P Layne; M Dembo
Journal:  Bull Math Biol       Date:  1989       Impact factor: 1.758

9.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 10.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.